Carmot Therapeutics Expands Leadership Team and Closes $47 Million Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3n69rOd
via IFTTT